Abstract
As new active agents are discovered and approved, it is clear that combinations of these immunotherapies will be needed to reject most human cancers. The era of personalized patient tumor analysis has arrived just in time to guide these combinations.
Cite
CITATION STYLE
APA
Yang, J. C. (2016). The immunotherapy roadmap. Clinical Cancer Research, 22(2), 275–276. https://doi.org/10.1158/1078-0432.CCR-15-2144
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free